CaDAnCe-302
BeOne Medicines
BeOne Medicines
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Dizal Pharmaceuticals
Fate Therapeutics
Merck Sharp & Dohme LLC
BeOne Medicines
Hoffmann-La Roche
Columbia University
Mayo Clinic
Acerta Pharma BV
Eli Lilly and Company
BeOne Medicines
University of Arizona
Thomas Jefferson University
City of Hope Medical Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
German CLL Study Group
The First Hospital of Jilin University
Thomas Jefferson University
Eli Lilly and Company
German CLL Study Group
German CLL Study Group
German CLL Study Group
Cedars-Sinai Medical Center
St. Petersburg State Pavlov Medical University
University of Giessen
AbbVie
M.D. Anderson Cancer Center
St. Petersburg State Pavlov Medical University
St. Petersburg State Pavlov Medical University
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Wake Forest University Health Sciences
Celgene
Fate Therapeutics
Fate Therapeutics
Hoffmann-La Roche
University of Wisconsin, Madison
Brown University
TG Therapeutics, Inc.
Yale University
University of Washington
Institute of Hematology & Blood Diseases Hospital, China
Arbeitsgemeinschaft medikamentoese Tumortherapie
Aptevo Therapeutics
Aptevo Therapeutics
Gilead Sciences
SecuraBio
St. Petersburg State Pavlov Medical University